Early viral kinetics: A novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 10, 2011, Pages 859-862

  Milazzo, Laura ^a   Cesari, Miriam ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Addiction Department   (Italy)

Author keywords

early virologic response; HCV kinetics; HIV HCV coinfection; twice weekly peg IFN 2a

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; INTERFERON STIMULATED GENE; MIXED INFECTION; MOLECULAR DYNAMICS; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; REVIEW; STANDARDIZATION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS GENE; VIRUS GENOME;

EID: 80053635628     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.100     Document Type: Review

References (16)

1. Murphy AA, Herrmann E, Osinusi AO et al. Twice-weekly pegylated interferon-a-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 25, 1179-1187 (2011
2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351, 438-450 (2004 (Pubitemid 38988593)
3. Rozenberg L, Haagmans BL, Neumann AU et al. Therapeutic response to peg-IFN-a-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 23, 2439-2450 (2009
4. Dahari H, Affonso de Araujo ES, Haagmans BL et al. Pharmacodynamics of PEG-IFN-a-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. J. Hepatol. 53(3), 460-467 (2010). 5 Van den Eynde E, Crespo M, Esteban JI et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: A pilot trial. Clin. Infect. Dis. 48(8), 1152-1159 (2009). 6 Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C viral kinetics in special populations. Curr. Hepat. Rep. 7(3), 97-105 (2008
5. Laguno M, Larrousse M, Murillas J et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J. Acquir. Immune Defic. Syndr. 44(2), 174-178 (2007 (Pubitemid 46292220)
6. Laufer N, Bolcic N, Rolon MJ et al. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antivir. Res. 90(1), 92-97 (2011). 9 EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. European Association for the Study of the Liver. J. Hepatol. 55, 245-264 (2011
7. Bruno R, Sacchi P, Ciappina V et al. Viral dynamics and pharmacokinetics of peginterferon a-2a and peginterferon a-2b in naive patients with chronic hepatitis C: A randomized, controlled study. Antivir. Ther. 9(4), 491-497 (2004 (Pubitemid 39150205)
8. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24(4), 778-789 (1996 (Pubitemid 26334273)
9. Roberts SK, Weltman MD, Crawford DH et al. Impact of high-dose peginterferon a-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology 50, 1045-1055 (2009
10. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-a-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Viral. Hepat. 10(4), 271-276 (2003 (Pubitemid 36801913)
11. Lurie Y, Rouzier-Panis R, Webster GJ et al. Optimal dosing frequency of pegylated interferon a-2b monotherapy for chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 3(6), 610-615 (2005 (Pubitemid 40824755)
12. Sebastiani G, Ferrari A, Boccato S, Pistis R, Alberti A. Clinical trial: Comparison of weekly once versus twice half-dose weekly administration of pegylated interferon a 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 26(7), 1077-1082 (2007 (Pubitemid 47416295)
13. Silva M, Poo J, Wagner F et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon a-2b and peginterferon a-2a in patients with chronic hepatitis C (COMPARE). J. Hepatol. 45, 204-213 (2006
14. de Araujo ES, Dahari H, Cotler SJ et al. Pharmacodynamics of PEG-IFN-[a]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J. Acquir. Immune Defic. Syndr. 56(2), 95-99 (2011
15. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med., 364, 2405-2416 (2011
16. Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon a-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre Phase 2 trial. Lancet 376, 705-716 (2010).